// App-Quantinova.ai

TPS5069 : Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant.

Researchers

Presenter

  • Mary-Ellen Taplin

Principal Investigators

  • Emmanuel S. Antonarakis

  • Daniel T. Dransfield

  • Karen J. Ferrante

  • Johann Sebastian De Bono

Medical Centers

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MAThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United KingdomTokai Pharma, Cambridge, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Metastatic castration-resistant prostate cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Androgen receptor

  • Androgen receptor variant 7

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Galeterone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved